Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and ICE Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma (NICE)
NCT03016871Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2017
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Hodgkin lymphoma (HL), sponsored by City of Hope. Started May 2017; status: active, not recruiting.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03016871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016871.